Concentric Capital Strategies LP Purchases New Stake in Ralliant Corporation $RAL

Concentric Capital Strategies LP acquired a new position in shares of Ralliant Corporation (NYSE:RAL) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 249,146 shares of the company’s stock, valued at approximately $12,684,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RAL. Cetera Investment Advisers bought a new position in shares of Ralliant in the second quarter valued at about $700,000. Russell Investments Group Ltd. bought a new position in Ralliant in the 2nd quarter valued at about $1,465,000. EverSource Wealth Advisors LLC acquired a new stake in Ralliant during the second quarter worth approximately $39,000. First Trust Advisors LP acquired a new stake in Ralliant during the second quarter worth approximately $2,013,000. Finally, Federated Hermes Inc. bought a new stake in shares of Ralliant during the second quarter worth approximately $326,000.

Ralliant Price Performance

Ralliant stock opened at $67.50 on Thursday. The stock has a fifty day moving average of $54.62 and a 200-day moving average of $50.26. The stock has a market capitalization of $7.56 billion and a P/E ratio of -6.17. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $70.22.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Analysts Set New Price Targets

RAL has been the subject of several research reports. Wall Street Zen cut Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Barclays upped their price target on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Citigroup lifted their price objective on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Finally, Truist Financial reaffirmed a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $67.30.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.